Gastrointestinal dysfunction in Parkinson's Disease
Section snippets
Introduction and epidemiology
Parkinson's disease (PD) is a progressive neurodegenerative disease of midaged or older adults. The pathophysiology of its varied symptoms still remains hypothetic. We still don't know [1] whether the pathologic process originates in the brain or elsewhere in the nervous system. Apart from the cardinal signs - bradykinesia, rigidity, tremor at rest and postural instability - in the very beginning, patients complain of hyposmia, REM-sleep behaviour disorders, depression, and constipation.
Anatomy and pathology
The vagal nerve extrinsically innervates the gastrointestinal tract from the esophagus to the left colic flexure, and is mainly responsible for the motility of both esophagus and stomach. The remaining colon is innervated by the parasympathetic nucleus of the spinal cord (S2-4). Sympathetic innervation (via prevertebral ganglia) of the small and large bowel appears to be less important [4]. Colonic motility is predominantly governed by the intramural ganglia, the enteric nervous system (ENS) –
Upper gastroinestinal tract
Motility disorders of the upper GI-tract have to date not been met with greater interest. Sialorrhea alone was a reported symptom, but was seldom seen in connection with dysphagias.
Patients with Parkinson's disease present with delayed and/or disturbed motility of the upper gastrointestinal tract, which is primarily marked by swallowing problems and impaired gastric emptying. The esophageal sphincters, however, are disturbed as well involving above all the synergy between propulsion and
Diagnostic exploration of the upper gastrointestinal tract
Measurements by breath tests have become established routine in everyday clinical life since they are a feasible and usually well tolerated procedure [17]. Gastric motility can, in addition, be determined on gastric emptying scintiscan after ingestion of a radioactive meal.
Treatment
Anticholinergics have so far been recommended to treat sialorrhea in Parkinson patients. It would nevertheless make more sense to address the causatively involved dysphagias in the first place. Injections with botulinum toxin [18] may be considered a therapeutic option.
Dysphagias are quite refractory to treatment. You can advise patients to adopt an antidysphagic or pap diet to avoid ingestion of larger bits of food. Prokinetic medication may be helpful in addition - domperidone for instance -
Lower GI-tract
Constipation has been identified as a rather frequent symptom in patients with Parkinson's disease ever since the first description of the disease [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30]. Today, constipation is considered the most common manifestation of autonomic dysfunction in this disease occurring at a prevalence in the range of 70 to 80% [20], [21], [22], [23], [31], [32], [33], [34], [35]. Compared to age- and sex-matched controls, constipation is
Effect of antiparkinsonian therapy
Constipation in Parkinson's disease is often viewed as an adverse effect of medications. In 1958, Schwab and England [27] described constipating effects of almost all substances administered in Parkinson's disease. However, the most pronounced effect on gastrointestinal motility is ascribed to treatment with anticholinergics and levodopa [39]. Anticholinergics in particular have been accused of having a definitely constipative effect which may occasionally result in the development of megacolon
Slow transit constipation
Increasing evidence suggests that delayed colonic transit in Parkinson's disease is caused by disordered autonomic regulation due to central and peripheral degeneration of parasympathetic nuclei. Such degenerations are found in the vagal nucleus and intermediolateral nucleus as well as in the myenteric and submucous plexus of the gastrointestinal tract. Within the latter structures, the presence of Lewy bodies and a depletion of dopamine-producing neurons may be rated as characteristic
Outlet obstruction
Mathers et al. [53] were the first to describe a completely different mechanism of constipation in PD, namely a paradoxical contraction of the voluntary sphincters during defecation leading to marked difficulties in rectal evacuation. The authors assume that such anomalies in anorectal function represent a focal form of dystonia [53]. The latter hypothesis is supported by the findings reported by other groups [23], [54], [55], in which several patients with Parkinson's disease were found to
Diagnosis
The most important step in the diagnosis of constipation is thorough history-taking followed by physical examination. Occasionally, a structured interview using special questionnaires may be helpful, too [34]. Questions are aimed at differentiating abnormalities of colonic transit from those of defecation. Special emphasis is also put on the medication used, i.e. anticholinergics, calcium channel blockers, antidepressants, and diuretics.
Colonic transit abnormalities can easily be quantified by
Therapy
The simplest measures in the treatment of constipation focus on a high fiber diet [62], psyllium preparations [63], and perhaps - physiotherapy. In earlier years, treatment merely consisted in ordering increased fluid intake and the frequent administration of enteroclysis [27]. Unfortunately, these measures are efficient in mild cases of constipation only, but there is no appreciable effect in patients with transit times of more than five days [38]. Thus, most patients with constipation
Discussion
Gastrointestinal disorders are very common and involve the entire gastrointestinal tract. They are observed in the early stage already [14], [52], [58], [63], and increasingly so as the disease keeps progressing. Whether the neurodegenerative process might be set off in the enteric nervous system after all, is a current issue of discussion [8].
The pathophysiology of gastrointestinal dysfunction in PD seems to be multifactorial. Delayed intestinal transit is most likely caused by defective
References (77)
- et al.
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology
Neurosci Lett
(2006) - et al.
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol Aging
(2003) - et al.
Megacolon and dilatation of the small bowel in parkinsonism
Gastroenterology
(1951) - et al.
Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test
Neurosci Lett
(2005) - et al.
Parkinson's disease
J Chronic Dis
(1958) - et al.
Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease
Auton Neurosci
(2001) - et al.
Esophageal Lewy bodies associated with ganglion cell loss in achalasia: Similarity to Parkinson's disease
Gastroenterology
(1984) - et al.
Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation
Lancet
(1995) - et al.
Excess burden of constipation in Parkinson's disease: a pilot study
Mov Disord
(2006) - et al.
Patient-reported autonomic symptoms in Parkinson disease
Neurology
(2007)
The effects of sympathectomy on the motility of the human gastrointestinal and biliary tracts
Gastroenterology
Where does Parkinson disease pathology begin in the brain ?
J Neuropathol Exp Neurol
Lewy bodies in the visceral autonomic nervous system in Parkinson's disease
Adv Neurol
Nervous system pathology in sporadic Parkinson disease
Neurology
Do -synuclein aggregates in autonomic plexuses predate Lewy body disorders?
Neurology
Swallowing abnormalities and their response to treatment in Parkinson's disease
Neurology
Qunatitative study of salivary secretion in Parkinson's disease
Mov Disord
Gastric Emptying in Parkinson's disease: Patients with and without response fluctuations
Neurology
Gastric emptying time and gastric motility in patients with Parkinson's disease
Mov Disord
Predictors of gastric emptying in Parkinson's disease
Neurogastroenterol Motil
Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications
Clin Neuropharmacol
Treatment of drooling in Parkinson's disease with botulinum toxin
Mov Disord
Megacolon and volvulus in Parkinson's disease
Radiology
Alimentary disorder in parkinsonism
Australas Ann Med
Gastrointestinal symptoms in Parkinson Disease: 18-month follow-up study
Mov Disord
Characterization of swallowing and defecation in Parkinson's disease
Am J Gastroenterol
Gastrointestinal symptoms in Parkinson's disease
Mov Disord
Parkinsonsche Krankheit (Paralysis agitans) und postencephalitischer Parkinsonismus
Archiv für Psychiatrie
Postural hypotension and low R-R interval variability in parkinsonism, spino-cerebellar degeneration, and Shy-Drager syndrome
Neurology
Hypotension caused by L-dopa
Br Med J
The influence of the type, duration, severity and levodopa treatment of Parkinson's disease on cardiovascular autonomic responses
Clin Autonom Res
Serum noradrenaline response to standing up in patients with Parkinson's disease
Eur Neurol
Autonomic nervous system disturbances in Parkinson's disease
Adv Neurol
Constipation in Parkinson's disease
Klin Wochenschr
Sympathetic skin response and R-R interval variation in Parkinson's disease
Mov Disord
Postural hypotension and low R-R interval variability in parkinsonism, spino-cerebellar degeneration, and Shy-Drager syndrome
Neurology
Parkinsonism: Natural history and clinical features
Br Med J
Cited by (172)
Inter-disciplinary team working in neuroimmunology can facilitate counteracting brain-drain in Ukraine due to war
2023, Brain, Behavior, and ImmunityLifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies: A population-based study in Southeast Minnesota
2023, Parkinsonism and Related DisordersThe multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids
2022, Neurobiology of DiseaseModeling dopamine dysfunction in autism spectrum disorder: From invertebrates to vertebrates
2022, Neuroscience and Biobehavioral ReviewsCitation Excerpt :Studies in mice (Anderson et al., 2007; Wang et al., 2012) and humans (Singaram et al., 1995) have demonstrated that dopaminergic neurons in the ENS are similarly susceptible to degeneration in PD. Indeed, PD is often accompanied by disturbances in GI motility including dysphagia, impaired gastric emptying, and constipation(Jost, 2010), which are thought to be due to ENS DA neuron degeneration and dysfunction. Epilepsy has been recognized as a common comorbidity of ASD for decades (Tuchman et al., 2010).
Neuropeptide-S prevents 6-OHDA-induced gastric dysmotility in rats
2021, Brain Research